Despite more than five million Australians visiting live theatrical performances in 2025, major companies like the Sydney Theatre Company and Queensland Theatre continue to record operational deficits. According to financial statements and industry data, rising labor costs, venue overhead, and the inherent economic limits of live performance—known as Baumol’s cost disease—prevent box office growth from translating into actual profit.
The Bottom Line
- Over 22% of Australians aged 15 and over attended a theatre performance in the 12 months prior to the Australian Bureau of Statistics’ 2025 General Social Survey.
- Major cultural institutions are running operational deficits despite surging ticket sales, with the Sydney Theatre Company logging an underlying operational deficit of A$8.76 million in 2025.
- Economists attribute this structural squeeze to “cost disease,” where live theatre cannot automate labor the way manufacturing does, leaving production wages to climb alongside the broader economy.
Audiences Are Filling Seats, But the Math Tells a Different Story
The appetite for live performance is undeniably there, as evidenced by recent cancellations of major tours like Waitress and Beetlejuice sparking public worry over ticket costs. But box-office popularity is no longer a shield against financial collapse. Here is the kicker: high attendance figures and rising ticket revenues are routinely swallowed whole by the staggering realities of modern production economics.
Consider the ledger at Queensland Theatre. In 2025, the company managed a 5.6% bump in its mainstage audience alongside a dramatic 42% leap in box-office revenue compared to the previous year. Yet, when the fiscal year closed, the books showed an A$989,000 deficit. Down in New South Wales, the Sydney Theatre Company generated a formidable A$28.75 million in revenue from continuing operations over the same period, only to face an underlying operational deficit of A$8.76 million before one-off funding and fundraising pulled the final tally into a modest surplus. Meanwhile, Bell Shakespeare saw its income crawl from $10.96 million to $11.47 million, while its expenses outpaced that growth entirely, jumping from $10.99 million to $12.87 million.
Here is where the financial architecture of the arts diverges sharply from traditional corporate enterprise. Arts organizations are not single-product entities designed solely to extract margin from a single ticket. Queensland Theatre, for instance, funnels significant resources into initiatives like the Scene Project—backed by the Rekindle Foundation—which brings scripts into regional communities to engage nearly 4,000 students in acting and directing. These educational and community outreach pillars require sustained capital that the commercial box office was never designed to carry on its own.
The Anatomy of a Production Budget
To understand why the arithmetic fails, look closely at what it costs to put a mid-scale professional work on its feet. Take a hypothetical production featuring 11 actors—itself a rare luxury in contemporary publicly funded theatre—rehearsing for four weeks before a four-week season. Under the minimum wage conditions laid out in the Media Entertainment & Arts Alliance’s (MEAA) Performers’ Collective Agreement 2026, compensating those performers alone requires a baseline investment of at least $154,400.
And that is before a single director, stage manager, set designer, costume technician, or backstage crew member is paid a cent. Theatre producer Suzanne Jones noted that just bringing the recent Australian production of The Book of Mormon to opening night demanded $11.5 million. When you factor in venue hire, performance rights, worker’s compensation, insurance, set construction, freight storage, and accommodation, the financial precipice becomes clear. Expenses accumulate rapidly, often locking in long before the first ticket is sold to an uncertain public.
The Unyielding Grip of Baumol’s Cost Disease
To diagnose this persistent crisis, economists often look back to a framework established in 1966 by William Baumol and William Bowen. Their research identified a fundamental flaw in the economics of live performance: while industries like manufacturing leverage technology and automation to continuously boost productivity and trim labor requirements without altering the final product, live theatre remains stubbornly human.
An automotive factory can introduce robotics to cut assembly time in half while delivering the exact same vehicle. A theatre company cannot. While a company could theoretically “increase productivity” by cutting its cast from eleven actors down to six, or by shrinking a two-hour drama into a brisk 90 minutes, that does not make the original production more efficient—it simply creates an entirely different, altered piece of art. Because wages and venue overhead continue to inflate alongside the rest of the broader economy, the labor-intensive core of live performance leaves producers trapped in an unyielding financial squeeze.
| Theatre Company | Box Office / Revenue Trend | Operational Outcome |
|---|---|---|
| Queensland Theatre | Audience up 5.6%; box office revenue up 42% | Recorded an A$989,000 deficit |
| Bell Shakespeare | Income rose from $10.96m to $11.47m | Expenses outpaced income, rising to $12.87m |
| Sydney Theatre Company | Generated $28.75m in continuing operations revenue | Underlying operational deficit of $8.76m (offset by fundraising) |
As arts administrators look toward the future, the challenge facing the sector is less about drawing bodies through the turnstiles and more about bridging the widening chasm between human-powered artistry and escalating economic realities. Until a sustainable model emerges that accounts for the unyielding human cost of live staging, the curtain will continue to rise on productions that struggle to pay for themselves.
The Conversation Continues
How do we balance accessible ticket pricing with the very real survival needs of working artists and staging crews? Share your thoughts and experiences in the comments below.
